FANAPT
FANAPT (iloperidone) is an atypical antipsychotic medication approved for use in adult patients. It is indicated for the treatment of schizophrenia and the acute treatment of manic or mixed episodes associated with bipolar I disorder. The drug serves as a therapeutic intervention for managing these specific psychiatric conditions in the adult population.
How FANAPT Works
While the precise mechanism of action is unknown, the efficacy of iloperidone is thought to be mediated through the antagonism of dopamine type 2 (D2) and serotonin type 2 (5-HT2) receptors. The medication also forms an active metabolite called P88, which possesses a receptor binding profile similar to the parent drug. By blocking these specific receptors in the brain, the drug helps manage the symptoms associated with schizophrenia and bipolar I disorder.
Details
- Status
- Prescription
- First Approved
- 2009-05-06
- Routes
- ORAL
- Dosage Forms
- TABLET
FANAPT Approval History
What FANAPT Treats
2 indicationsFANAPT is approved for 2 conditions since its original approval in 2009. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Schizophrenia
- Bipolar I Disorder
FANAPT Boxed Warning
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. FANAPT is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1) ] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psych...
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. FANAPT is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1) ] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. FANAPT is not approved for use in patients with dementia-related psychosis. ( 5.1 )
Drugs Similar to FANAPT
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
FANAPT FDA Label Details
ProIndications & Usage
FDA Label (PDF)FANAPT ® is indicated for: Treatment of schizophrenia in adults [see Clinical Studies ]. Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies ] . FANAPT is an atypical antipsychotic indicated for: Treatment of schizophrenia in adults. Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. FANAPT is not approved for the treatment of patients with dementia-related psychosis [see Warnings and...
FANAPT Patents & Exclusivity
Patents (392 active)
Exclusivity
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.